Navigation Links
Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:10/14/2010

tate or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  Anadys believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is developing ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, Anadys has completed 12 weeks of dosing ANA598 added to current standard of care. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' expectations regarding its proposed public offering, Anadys' expected use of proceeds from the offering, Anadys' development programs including the anticipated timing for commencement of its Phase IIb study of ANA598, and Anadys' ability to develop novel medicines in the area of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, there are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. In addition, the results of preclinical and early clinical studies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... BALTIMORE, June 9, 2011 Paragon Bioservices, Inc., ... announced today that representatives from the company will ... One-on-One Partnering Meetings being held on June 27-30 ... Convention Center. Founded in 1990, ...
... Calif. and OXFORD, Miss., June 9, 2011 ... University of Mississippi today announced the university has granted ... to a potential new therapeutic use for pterostilbene (tero-STILL-bean) ... an ultra-pure formulation of pterostilbene, a compound found in ...
Cached Medicine Technology:Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention 2ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi 2ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi 3
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Just ... seriously, they must consider their own financial and marketing ... and weak marketing campaigns to the next level by ... Cloud Call Center, IVR, Voice Broadcast, Call Tracking and ... a 98% open rate, text messages are quickly become ...
(Date:7/24/2014)... Executives (ASAE) announced its 2014 Power of A Award ... of Anesthesiologists (ASA). , The ASA Global Humanitarian ... Award, one of the top honors from ASAE. GHO ... world through education on the global anesthesia crisis and ... ASA was also honored with a Power of A ...
(Date:7/24/2014)... (DM) appears to increase the risk for head and neck ... people with DM, but the risk of HNC in patients ... neck cancer is the sixth most common type of cancer. ... for an estimated 650,000 new cancer cases and 350,000 cancer ... Health Insurance Research Database to examine the risk of HNC ...
(Date:7/24/2014)... Primary care treatment of overweight and obese preschoolers ... compared to when only the child is targeted, according ... and conducted at the University at Buffalo and Women ... study were overweight or obese and had one parent ... or obese, according to body mass index (BMI) measurements, ...
(Date:7/24/2014)... Drinking caffeine may worsen the hot flashes and night ... go through menopause, new survey data suggests. "While ... caffeine intake may be useful for those postmenopausal women ... researcher Dr. Stephanie Faubion, director of the Women,s Health ... But caffeine -- a stimulant found in coffee and ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2
... Systems, a premier,provider of integrated professional and technical ... announced today that the Texas,Organization of Rural and ... Health Systems, Inc. endorsed vendor status.,Prior to endorsing ... certain the vendor is qualified to serve its ...
... Leadership authority is,critical for market research high ... leader to help optimize the market research group. ... market research,groups -- where top companies employ a ... and activities across Market,Research divisions, units and geographies., ...
... Passing ABC Plan; Urges Senate to,Act Quickly, ... today praised the House of Representatives for taking ... to Basic Care (PA ABC) plan,and he urged ... PA ABC would provide access to health care ...
... Also Announces Internal Controls and Procedures Improvements, Corporate, ... MCLEAN, Va., March 18 Sunrise Senior Living,Inc. ... informed the New York Stock,Exchange ("NYSE") that the Company ... deadline for filing its 2006 Form 10-K. The Company ...
... beneficial effects on human health, have been used for ... disorders. However, the ways in which probiotic bacteria elicit ... the action mechanisms could be the ability to induce ... At present there is only a limited amount of ...
... The Gram negative bacterium H pylori is involved in ... gastric carcinoma. Adhesion of the bacteria to the gastric ... , It is therefore important to know factors that ... MUC1, a mucin with a highly variable repetitive region ...
Cached Medicine News:Health News:Texas Organization of Rural and Community Hospitals (TORCH) Awards Phoenix Health Systems Endorsed Vendor Status 2Health News:Create Strong Leadership to Add Value to Market Research Function 2Health News:Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvania's Uninsured 2Health News:Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvania's Uninsured 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 2Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 5Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 6Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 7Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 8Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 9Health News:Do bacterial combinations result in enhanced cytokine production? No! 2
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with 7 mm tying surface. Wide serrated handle, polished finish. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Serrated handle with polished finish. Most popular size or model. Overall length 4 inches....
Medicine Products: